BofA warns Fed risks policy mistake with early rate cuts
On May 30, 2025, Fred P. Lampropoulos, the President and CEO of Merit Medical Systems Inc. (NASDAQ:MMSI), a $5.6 billion market cap medical device company, sold 10,000 shares of the company’s common stock. The shares were sold at a weighted average price of $95.12, resulting in a total transaction value of $951,200. Following this sale, Lampropoulos holds 1,056,028 shares directly. According to InvestingPro, the company maintains a "GREAT" financial health score.
This transaction is part of Lampropoulos’s ongoing management of his holdings in Merit Medical Systems, a company known for its medical devices and technology. The shares sold were part of multiple transactions, with prices ranging from $95.01 to $95.23. With analyst price targets ranging from $100 to $122 and strong revenue growth of 8.2% over the last twelve months, the company continues to show promising performance metrics. Lampropoulos has committed to providing full details of the sales to interested parties upon request. For deeper insights into MMSI’s valuation and growth prospects, check out the comprehensive research available on InvestingPro.
In addition to his direct holdings, Lampropoulos also holds shares indirectly through various means, including by his spouse and through a 401(k) plan. The indirect holdings include 7,734 shares by his spouse and 97,892 shares through the 401(k) plan.
Merit Medical Systems continues to be a significant player in the medical device sector, and this transaction reflects ongoing activity by its leadership in managing personal investments.
In other recent news, Merit Medical Systems has been active with several significant developments. The company has completed the acquisition of Biolife Delaware L.L.C. for $120 million in cash, which is expected to contribute $10 to $11 million in revenue for fiscal year 2025. Merit Medical (TASE:BLWV) anticipates that this acquisition will be slightly dilutive to non-GAAP earnings per share in 2025 but accretive to non-GAAP gross margin and operating margin in 2026. Canaccord Genuity responded to this acquisition by raising Merit Medical’s price target to $112 while maintaining a Buy rating.
Additionally, Merit Medical reported successful outcomes from its WRAPSODY CIE device trials, which have been approved by Health Canada, enhancing its hemodialysis treatment offerings. The device has shown superior performance in maintaining primary patency over traditional methods. Meanwhile, Needham analysts adjusted their outlook on the company, reducing the price target to $100 from $116, yet reaffirming a Buy rating. This adjustment followed Merit Medical’s first-quarter earnings report, which exceeded consensus estimates for revenue and earnings per share, despite tariff impacts.
Merit Medical’s management maintained its 2025 revenue forecast but revised its EPS guidance downward due to these tariffs. The company confirmed expected sales for the WRAPSODY device between $7 million and $9 million in 2025. Furthermore, Merit Medical reported a notable increase in gross and operating margins year-over-year, reflecting strong operational performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.